Figure 1.
TPF and cinobufotalin decrease viability of UMSCC5 and FADU cells synergistically.
Notes: (A) FADU cells treated by serial concentrations of cinobufotalin, or combined with IC50 concentration of TPF for 3 days and (B) FADU cells treated by serial concentrations of TPF, or combined with IC50 concentration of cinobufotalin for 3 days were detected by CCK-8 kit for the viability alterations, and the IC50 is calculated by the viability curve. (C) UMSCC5 cells treated by serial concentrations of cinobufotalin, or combined with IC50 concentration of TPF for 3 days and (D) UMSCC5 cells treated by concentrations of TPF, or combined with IC50 concentration of cinobufotalin for 3 days were detected by CCK-8 kit for the viability alterations, and the IC50 is calculated by the viability curve.
Abbreviations: CCK-8, cell counting kit-8; TPF, a mixture comprising paclitaxel, cisplatin, and 5-fluorouracil.